Imugene completes $2m placement
Tuesday, 17 June, 2003
Veterinary biotechnology company Imugene has completed a $AUD2 million placement to institutional and professional high net worth investors.
The funds raised by the placement, which was undertaken with Southern Cross Equities and Taylor Collison, will be put towards the company's companion and production animal vaccines.
"These funds will be used to strengthen our financial position and 'fast track' the development and commercialisation activities of the Company's veterinary products," said executive chairman Graham Dowland.
"We are encouraged by the institutional and high net worth client base who have participated in the placement, many of whom have been impressed with the Company's 'biological' vaccines, which are viable alternatives to the existing antibiotics and chemical treatments for production animals and pets."
Dowland said that the placement would be conditional upon the approval of shareholders for the buyout of VectoGen, currently 40 per cent owned by Imugene, and the subject of a General Meeting on June 23rd, 2003.
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
